Recurrent urinary tract infections (UTIs) present a major clinical challenge in postmenopausal individuals. Consequently, clinicians frequently prescribe topical hormone therapy to restore normal urogenital flora. A randomized trial evaluated whether periurethral estrogen application is noninferior to standard intravaginal instillation for UTI prophylaxis. In fact, the findings demonstrate that applying estrogen cream directly to the periurethral area achieves comparable clinical efficacy.
Key Findings on Periurethral Estrogen Application
The TAPER trial randomized 114 postmenopausal participants into two equal groups of 57 patients. Specifically, one group used a 1.0 g intravaginal estradiol applicator twice weekly. Meanwhile, the second group received 0.5 g of cream via digital application to the periurethral region. At 6 months, 50.9% of participants in the periurethral group remained completely UTI-free. Similarly, 52.6% of participants in the intravaginal group remained free of infection. Therefore, periurethral delivery met statistical noninferiority criteria for preventing UTI recurrence.
Secondary Outcomes and Patient Tolerability
In addition, both administration methods successfully reduced vaginal pH levels after 6 months of treatment. Furthermore, the reduction in vaginal pH did not differ significantly between the two treatment arms. However, patient-reported adverse effects varied markedly based on the application technique. Notably, participants using intravaginal applicators experienced significantly higher rates of vaginal itching at 3 months. Specifically, 24.0% of intravaginal users reported itching compared to only 2.4% of periurethral users. As a result, digital periurethral application provides better local tolerability for many patients.
Clinical Implications for Practice
Postmenopausal patients often struggle with applicator insertion or fear deep intravaginal administration. Consequently, non-adherence remains a common obstacle in long-term UTI prophylaxis. Offering digital periurethral placement gives clinicians an effective, patient-friendly alternative. Moreover, using half the dose periurethrally achieves equivalent biological and clinical protection. Thus, this approach enhances patient compliance while reducing localized side effects.
Frequently Asked Questions
Q1: Is periurethral estrogen application as effective as intravaginal application for UTI prevention?
Yes. The trial showed that 50.9% of patients using periurethral application remained UTI-free at 6 months, compared to 52.6% using intravaginal application, proving noninferiority.
Q2: Does periurethral application cause fewer side effects?
Yes. Patients applying estrogen cream periurethrally experienced significantly less vaginal itching (2.4%) compared to those using intravaginal applicators (24.0%).
Q3: What dose of estrogen cream was used for periurethral application in the trial?
Participants used 0.5 g of estradiol cream applied digitally to the periurethral area twice weekly, compared to 1.0 g used intravaginally.
References
- Zuo SW et al. Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial. Obstet Gynecol. 2026 Jul 27. doi: 10.1097/AOG.0000000000006376. PMID: 42492951.
- Tan-Kim J, Shah NM, Menefee SA. Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women. Am J Obstet Gynecol. 2023.